Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
T-cell Large Granular Lymphocyte Leukemia: early-phase trial registry
2 of 3 indexed T-cell Large Granular Lymphocyte Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
T-cell Large Granular Lymphocyte Leukemia: 3 US clinical trials tracked, 2 recruiting.
T-cell Large Granular Lymphocyte Leukemia is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Jonathan Brammer, running 2 of these trials.
Enrollment posture brief
Registry condition t-cell-large-granular-lymphocyte-leukemia
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
T-cell Large Granular Lymphocyte Leukemia lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for T-cell Large Granular Lymphocyte Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
T-cell Large Granular Lymphocyte Leukemia is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
NCT05010005
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Jonathan Brammer
NCT05592015
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Jonathan Brammer
NCT05141682
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on T-cell Large Granular Lymphocyte Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on T-cell Large Granular Lymphocyte Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this T-cell Large Granular Lymphocyte Leukemia page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 T-cell Large Granular Lymphocyte Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jonathan Brammer sponsors the most T-cell Large Granular Lymphocyte Leukemia trials on record, review their full trial history before evaluating a specific study. See Jonathan Brammer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This T-cell Large Granular Lymphocyte Leukemia condition card totals 3 registered trials; most-linked intervention Ruxolitinib; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.